Details of the Drug Combinations

General Information of This Drug (ID: DM7BN0X)

• Drug Name: Esomeprazole (DM7BN0X)
• Synonyms: Esomeprazolum; Nexiam; Inexium paranova; Axagon (TN); Esomeprazole (INN); Esomeprazole [INN:BAN]; Esopral (TN); Inexium paranova (TN); Lucen (TN); Nexiam (TN); Nexium (TN); Sompraz (TN); Zoleri (TN); (S)-(-)-Omeprazole; (S)-Omeprazole; 5-Methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole; 5-methoxy-2-{(S)-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole; 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1-methyl-1H-benzimidazole

Indication

Cystic fibrosis; ICD 11: CA25; Status: Approved [1]; Gastrinoma; ICD 11: 2C10.1; Status: Approved [1]; Laryngeal disorder; ICD 11: N.A.; Status: Approved [1]; Nausea; ICD 11: MD90; Status: Approved [1]; Peptic esophagitis; ICD 11: N.A.; Status: Approved [1]; Peptic ulcer; ICD 11: DA61; Status: Approved [2]

• Therapeutic Class: Antiulcer Agents
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

30 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Aspirin + Esomeprazole	DC82N1Y	Aspirin	Peptic ulcer	[3]
Clarithromycin + Esomeprazole	DCB6MI5	Clarithromycin	Helicobacter Pylori Infection	[4]
Clarithromycin + Esomeprazole	DC6QPNU	Clarithromycin	Helicobacter Pylori Infection	[5]
Clarithromycin + Esomeprazole	DCIDFPG	Clarithromycin	Helicobacter Pylori	[6]
Esomeprazole + Levofloxacin	DC6IVT1	Levofloxacin	Helicobacter Pylori Infection	[7]
Esomeprazole + Levofloxacin	DC5OPJP	Levofloxacin	Helicobacter Pylori Infection	[7]
Esomeprazole + Doxycycline	DCTCCRU	Doxycycline	GASTRITIS	[8]
Esomeprazole + Methylprednisolone	DC1WOD0	Methylprednisolone	Thyroid-associated Ophthalmopathy	[9]
Esomeprazole + Aspirin	DCAJ1HN	Aspirin	Esophageal Cancer	[10]
Esomeprazole + Amoxicillin	DCU8C52	Amoxicillin	Helicobacter Pylori Infection	[4]
Esomeprazole + Isavuconazole	DC6AS4V	Isavuconazole	Pharmacokinetics of Isavuconazole	[11]
Esomeprazole + Itraconazole	DCRW12B	Itraconazole	Achlorhydria	[12]
Esomeprazole + MLN8237	DCWIVAW	MLN8237	Solid Tumors	[13]
Omeprazole + Esomeprazole	DC4ANWN	Omeprazole	Reflux Esophagitis	[14]
Clarithromycin + Esomeprazole	DCO0PI4	Clarithromycin	Treatment Effectiveness	[15]
Rifabutin + Esomeprazole	DCA81FZ	Rifabutin	Helicobacter Infections	[16]
Clarithromycin + Esomeprazole	DC8ORUL	Clarithromycin	Helicobacter Pylori Infection	[17]
Clarithromycin + Esomeprazole	DC995M7	Clarithromycin	Gastritis	[18]
Clarithromycin + Esomeprazole	DC05BRR	Clarithromycin	Helicobacter Pylori Infection	[19]
Clarithromycin + Esomeprazole	DC155DP	Clarithromycin	Functional Dyspepsia	[20]
Clarithromycin + Esomeprazole	DC2PC9B	Clarithromycin	Helicobacter Pylori Infection	[21]
Esomeprazole + Potassium Citrate	DCBKP42	Potassium Citrate	Helicobacter Infections	[22]
Esomeprazole + Esomeprazole	DC0QQ5U	Esomeprazole	Colorectal Neoplasms	[23]
Esomeprazole + Moxifloxacin	DC48T1G	Moxifloxacin	Helicobacter Infections	[22]
Esomeprazole + Metronidazole	DCM2TO6	Metronidazole	Helicobacter Pylori Infection	[24]
Esomeprazole + Levofloxacin	DCPJ5KC	Levofloxacin	Helicobacter Pylori Infection	[25]
Esomeprazole + Metronidazole	DCKOGVI	Metronidazole	Helicobacter Pylori Infection	[26]
Esomeprazole + Amoxicillin	DCZGJ2O	Amoxicillin	Helicobacter Pylori Infection	[24]
Rebamipide + Esomeprazole	DC2K7X3	Rebamipide	Dyspepsia	[27]
Tindamax + Esomeprazole	DCOADDT	Tindamax	Helicobacter Infection	[28]

1 Approved Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Esomeprazole + Aspirin	DC4UZ5T	Aspirin	Cardiovascular disease	[29]

References

• [1] Esomeprazole FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5488).
• [3] An overview of proton pump inhibitors. Gastroenterol Nurs. 2003 Sep-Oct;26(5):182-90.
• [4] ClinicalTrials.gov (NCT03383003) Comparison of Two Novel First-line Anti-Helicobacter Pylori Therapy
• [5] ClinicalTrials.gov (NCT05189444) The Evaluation of Triple Therapy With Vonoprazan, Amoxicillin and Bismuth for Eradication of Helicobacter Pylori
• [6] ClinicalTrials.gov (NCT04753437) A Study of Vonoprazan in Adults With Helicobacter Pylori
• [7] ClinicalTrials.gov (NCT02596620) Levofloxacin-containing Therapies In Second Line Helicobacter Pylori Eradication
• [8] ClinicalTrials.gov (NCT02884713) Levofloxacin-Doxycycline for Helicobacter Pylori Eradication in Saudi Arabia
• [9] ClinicalTrials.gov (NCT01579539) The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy
• [10] ClinicalTrials.gov (NCT00357682) A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia
• [11] ClinicalTrials.gov (NCT02128893) A Study to Evaluate the Effect of Multiple Doses of Esomeprazole on the Pharmacokinetics of Isavuconazole
• [12] ClinicalTrials.gov (NCT04942652) Study to Evaluate Effects of Food or Proton Pump Inhibitor on the Pharmacokinetics of Itraconazole in Healthy Volunteers
• [13] ClinicalTrials.gov (NCT01844583) Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib
• [14] ClinicalTrials.gov (NCT00634114) Reflux Esophagitis Phase III Study (Maintenance Treatment)
• [15] ClinicalTrials.gov (NCT06162949) Vonoprazan for Helicobacter Pylori Eradication in Adolescents
• [16] ClinicalTrials.gov (NCT04652284) Effectiveness of Rifabutin for Treatment of Helicobacter Pylori
• [17] ClinicalTrials.gov (NCT04090021) Genotypic Resistance-guided Versus Empirical Therapy for H. Pylori Eradication.
• [18] ClinicalTrials.gov (NCT02296021) Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Bismuth-containing Quadruple Therapy
• [19] ClinicalTrials.gov (NCT02732249) Clarithromycin Triple Therapy Plus Bismuth for Helicobacter Pylori First-line Treatment
• [20] ClinicalTrials.gov (NCT01667575) Efficiency Study of Clarithromycin and Bismuth-containing Quadruple Therapy to Treat H.Pylori
• [21] ClinicalTrials.gov (NCT02552641) Food Effect on the Eradication Rate of H. Pylori With Triple Therapy With Esomeprazole
• [22] ClinicalTrials.gov (NCT01792700) Long-term Follow up Helicobacter Pylori Reinfection Rate After Second-Line Treatment: Bismuth-Containing Quadruple Therapy Versus Moxifloxacin-Based Triple Therapy
• [23] ClinicalTrials.gov (NCT02800330) The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib
• [24] ClinicalTrials.gov (NCT04024527) High Dose of Dual Therapy Plus Metronidazole for Helicobacter Pylori RescueTreatment
• [25] ClinicalTrials.gov (NCT04432233) Intravenous Triple Therapy in the Treatment of Helicobacter Pylori Infection and Related Complications Caused by Active Peptic Ulcer Disease
• [26] ClinicalTrials.gov (NCT03557437) High Dose of Amoxicillin and Metronidazole Plus Bismuth For Helicobacter Pylori Treatment
• [27] ClinicalTrials.gov (NCT02134405) Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia
• [28] ClinicalTrials.gov (NCT02711176) Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection
• [29] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015